We will develop and commercialize high-value, multi-marker, diagnostic tests which address unmet needs in gynecologic oncology and women’s health. We will accomplish our mission through internal development, targeted acquisitions, and collaborations with leading scientific and clinical institutions. Our global commercial efforts will include direct marketing and sales activities as well as partnerships with leading companies in women’s health.

Patents show all

Vermillion has 1 licensable patents.
339Applications182Issued

Clinical Trials show all

2N/A

SEC Filings show all

8-K22010-Q5210-K15D3S-11

Contact Information

12117 Bee Caves Road, Building Three, Suite 100
Austin, TX 78738
United States

512-519-0400

    Overview

    Total FundingEmployeesLast Funding DateStatus
    $89,992,35811-502017-02-14Ipo

    Crunchbase Investment Rounds

    DateAmountRoundValuationLead InvestorOther Investors
    2014-12-23$10,500,000Post_ipo_equityOracle Investment Management Inc., Birchview Fund, Jack Schuler
    2013-05-24$13,242,500Post_ipo_equityOracle Investment Management Inc.
    2017-02-14$5,600,000Post_ipo_equity
    2013-12-20$17,600,000Post_ipo_equityOracle Investment Management Inc., Matthew W. Strobeck, Jack Schuler
    2010-01-12$43,049,858Post_ipo_equity

    SEC Form D Funding Events

    DateOfferedSoldType
    2013-05-24$13,242,500$13,242,500Equity, Option to Acquire
    2010-01-12$43,049,858$43,049,858Equity
    2007-09-17UnknownUnknownOther (Paper Filing)

    Key Executives

    • Gail S. Page
      Director
    • John F. Hamilton
      Director
    • James S. Burns
      Director
    • Thomas McLain
      Executive Officer
    • Eric Schoen
      Executive Officer
    • Donald Munroe
      Executive Officer
    • William Creech
      Executive Officer
    • Bruce Huebner
      Director
    • James Burns
      Director
    • Peter Roddy
      Director
    • Carl Severinghaus
      Director
    • William Wallen
      Director
    • Robert Goggin
      Director